BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28032599)

  • 1. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
    Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
    Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.
    Wu HM; Schally AV; Cheng JC; Zarandi M; Varga J; Leung PC
    Cancer Lett; 2010 Dec; 298(1):16-25. PubMed ID: 20630651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
    Guo J; Schally AV; Zarandi M; Varga J; Leung PC
    Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twist modulates human trophoblastic cell invasion via regulation of N-cadherin.
    Ng YH; Zhu H; Leung PC
    Endocrinology; 2012 Feb; 153(2):925-36. PubMed ID: 22166980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells.
    Chang LH; Chen CH; Huang DY; Pai HC; Pan SL; Teng CM
    J Cell Physiol; 2011 Apr; 226(4):1060-8. PubMed ID: 20857420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone regulates human trophoblastic cell invasion via TWIST-induced N-cadherin expression.
    Peng B; Zhu H; Leung PC
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E19-29. PubMed ID: 25313909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
    Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
    J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
    Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV
    Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
    Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
    J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
    Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
    Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC.
    Zhao N; Sun H; Sun B; Zhu D; Zhao X; Wang Y; Gu Q; Dong X; Liu F; Zhang Y; Li X
    Sci Rep; 2016 Mar; 6():23091. PubMed ID: 26980408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.
    Wu HM; Wang HS; Huang HY; Lai CH; Lee CL; Soong YK; Leung PC
    BMC Cancer; 2013 Jun; 13():300. PubMed ID: 23786715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of RbAp48 knockdown on migration and invasion of human cervical cancer cell line MS751 in vitro].
    Zhong J; Yang X; Mai M; Wang D; Lv L; Rao J
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1564-9. PubMed ID: 26607076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
    Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist.
    Sun X; Cui M; Zhang A; Tong L; Wang K; Li K; Wang X; Sun Z; Zhang H
    J Exp Clin Cancer Res; 2016 Jan; 35():10. PubMed ID: 26762267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines.
    Dong P; Kaneuchi M; Watari H; Sudo S; Sakuragi N
    Mol Carcinog; 2014 May; 53(5):349-59. PubMed ID: 24002805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.